Nomura Y
Dept. of Breast Surgery, National Kyushu Cancer Center.
Gan To Kagaku Ryoho. 1996 Dec;23(14):1911-5.
The significance of doxorubicin (ADR) was reviewed in the treatment of advanced as well as early breast cancer. The history of ADR treatment, mainly as a combination of CAF, or FAC, has revealed that ADR is still the key drug for breast cancer, the response rate being 40-60%. A multivariate analysis in 182 advanced breast cancer cases showed that the predictive factor was the dominant site of metastasis, and performance status (PS). Overall survival was determined with the age, the dominant site of metastasis, and PS. Recently the combination chemotherapy including ADR was evaluated to be equivalent to CMF type chemotherapy in the adjuvant settings.
回顾了阿霉素（ADR）在晚期及早期乳腺癌治疗中的意义。ADR的治疗史，主要是作为CAF或FAC联合方案，已表明ADR仍然是乳腺癌的关键药物，有效率为40%-60%。对182例晚期乳腺癌病例的多因素分析显示，预测因素为转移的主要部位和体能状态（PS）。总生存期由年龄、转移的主要部位和PS决定。最近，在辅助治疗中，含ADR的联合化疗被评估为与CMF型化疗等效。
